3
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Myeloid
7
Other hematologic neoplasm
3
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Lymphoma
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Lymphoma, Non-Hodgkin
2
Leukemia, B-Cell
2
Leukemia
2
Sezary Syndrome
1
Recurrence
1
Primary Myelofibrosis
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
54
fludarabine phosphate
48
Peripheral Blood Stem Cell Transplantation
37
Tacrolimus
36
Mycophenolic Acid
35
Whole-Body Irradiation
30
Busulfan
29
Antilymphocyte Serum
26
Cyclosporine
23
Methotrexate
21
fludarabine
19
Melphalan
18
Filgrastim
18
Radiotherapy
13
Methylprednisolone
12
Etoposide
12
Cord Blood Stem Cell Transplantation
12
thymoglobulin
11
Sirolimus
11
Psychiatric Rehabilitation
9
Flow Cytometry
9
Stem Cell Transplantation
7
Granulocyte Colony-Stimulating Factor
7
Therapeutics
6
sargramostim
5
ruxolitinib
5
Specimen Handling
5
Polymerase Chain Reaction
5
Cytarabine
5
Cyclosporins
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Primary Myelofibrosis
×
navitoclax
×
Lymphoid
×
Clear all
NCT03592576
2024-05-06
Expanded Access to Navitoclax
AbbVie
No longer available